5HT3 Receptor Antagonists Market - Forecast(2024 - 2030)

Report Code: HCR 1455 Report Format: PDF + Excel

5HT3 Receptor Antagonists Market Overview

The 5HT3 receptor antagonist market size is estimated to reach $6.3 billion by 2026. Furthermore, it is poised to grow at a CAGR of 5.7% over the forecast period of 2021-2026. 5HT3 receptor antagonists, also known as serotonin blockers, belong to a drug category that is prevalently used to treat and prevent nausea and vomiting. FDA has more importantly approved these drugs in cases of cancer chemotherapy, radiation therapy, and even post-operation. Serotonin is released in the gastrointestinal tract post-chemotherapy; further, it binds to the receptors within the brain, which induces vomiting and nausea. The 5HT3 receptors stop the binding process and hence prevents cases of nausea and vomiting. Dexamethasone, a steroidal drug used to reduce the body’s inflammation levels, has proven to be an effective drug in preventing cases of nausea post-operation or even in chemotherapy. The increase in the prevalence of cancer worldwide, the use of chemotherapy as an effective treatment method, and the development of best-in-class drugs to prevent any side effects post medications are some of the factors driving the 5HT3 receptor antagonist industry during the forecast period of 2021-2026.

5HT3 Receptor Antagonists Market Report Coverage

The report: 5HT3 Receptor Antagonists Market Forecast (2021-2026)”, by Industry ARC covers an in-depth analysis of the following segments of the HPV Testing and Pap Test Market.

By Product Type- First Generation Serotonin Blockers and Second-Generation Serotonin Blockers. 
By Application – Chemotherapy-Induced Nausea and Vomiting, Radiation-Induced Nausea and Vomiting, and Post Operative Nausea and Vomiting. 
By Route of Administration- Intravenous, Topical Patches, and Oral. 
By Distribution Channel – Hospital Pharmacy, Drugstore, Online Pharmacy, and Others.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa)

Key Takeaways

  • Geographically, Asia-Pacific’s 5HT3 receptor antagonist market held the largest market share in the year 2020. It is owing to a substantial increase in the total number of cancers cases and using the serotonin blockers to address the after-effects of chemotherapy. However, North America is set to offer lucrative growth opportunities as the region is seeing a steep rise in the diagnosed cancer cases, and the government expenditure to aid the disease is also seeing an upward trend.
  • An increase in disposable income along with a high incidence of melanoma cells causing cancer across the world region is a driver for the market. However, the side effects post-consumption of such drugs is a ready market challenge.
  • Detailed analysis of the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the 5HT3 receptor antagonist report.
5HT3 Receptor Antagonists Market Segment- By Geography (%) for 2020

5HT3 Receptor Antagonists Market

For More Details on This Report - Request for Sample

5HT3 Receptor Antagonists Market Segment Analysis- By Product Type

The 5HT3 Receptor Antagonists Market based on product type can be further segmented into first-generation serotonin blockers and second-generation serotonin blockers. The first-generation serotonin blocker held a dominant market share in the year 2020. It is owing to the easy availability and most of the drug’s presence to take via the oral form. Furthermore, these drugs cost less than its counterpart. For example, 5mL injection for ondansetron costs $1.87, while the second-generation drug known as palonosetron costs $8.78 per 5mL. Moreover, the cancer prevalence in low-HDI and medium HDI countries propel their usage.

However, the second-generation serotonin blocker is estimated to be the fastest-growing segment, with a CAGR of 6.1% over the forecast period of 2021-2026. It is owing to its capability to bind faster and more strongly to the nerve receptors and provide its effect for a longer duration of time. Moreover, it also binds to the receptors in the brain. Moreover, second-generation drugs are capable of handling CINV in patients with severe and solid tumors.

5HT3 Receptor Antagonists Market Segment Analysis- By Route of Administration

The 5HT3 receptor antagonists market based on the route of administration can be further segmented into intravenous, topical patches, and oral. The oral segment held the dominant market share in the year 2020. It is owing to ease of providing medicines in non-clinical setups, and moreover providing the same efficacy results throughout. As per various studies, a palonosetron 0.50-mg oral dose has been favored to prevent CINV in patients receiving moderately emetogenic chemotherapy due to a numerical gain in efficacy without a side effect disadvantage. However, the intravenous sub-segment is estimated to be the fastest-growing, with a CAGR of 6.4% over the forecast period of 2021-2026. It is owing to the reliance of dexamethasone on the second-generation IV formulations, as they can only be provided via IV administration. Moreover, the medicine/ drug is directly delivered into the patient’s bloodstream, rather than being first observed into their stomach.  

5HT3 Receptor Antagonists Market Segment Analysis- By Geography

The 5HT3 receptor antagonists market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. Geographically, Asia-Pacific held the dominant market share of 31% as compared to the other regions. It is owing to the prevalence and high incidence of various cancer in this region. For example, the number of new cases diagnosed in Asia-Pacific in 2020 was 9.5 million, while the total diagnosed patients were close to 19.1 million globally, which is 49.3%. The mortality due to which was also close to 55%. The grade 1 or first-generation serotonin blockers were predominantly used due to their low costs and oral application.

However, North America is set to offer lucrative growth opportunities. As estimated by the WHO and Globocan, the regions with High HDI will see an exponential rise in cancer cases owing to better life expectancy. Moreover, the incidence rate compared to the world is significantly higher. These regions' governments spend billions of dollars each year to support better treatment facilities, which will continue to see an increasing allotment in the coming years. The following factors will drive the market.

5HT3 Receptor Antagonists Market Drivers

The increasing incidence of cancer which is supported by chemotherapy needs 5HT3 as a serotonin blocker. This is likely to drive the market in the forecast period. 

It is of no surprise that the prevalence and incidence of cancer cases worldwide have increased many-fold. Moreover, WHO believes that the world would see a 47% increase from the current cancer cases, estimated to be 19.3 million in 2020. Cancer chemotherapy utilizes anti-cancer drugs in its regime, which affects the patient's gastrointestinal tract. The use of serotonin blockers has helped patients worldwide to address such issues. For example, about 70-80% of all cancer patients develop the problem known as CINV. Furthermore, pharmaceutical companies have made advancements to provide topical patches that need not be digested or taken intravenously but exhibit the same chemical properties.

The correlation between rising age and developing cancer to use the 5HT3 receptor antagonists is anticipated to boost the market growth.

As per WHO, the countries where with High HDI or Human Development Index would see an exponential rise in cancer-related issues. Human Development Index considers the average life expectancy, education, and other critical demographic parameters in its account. Moreover, half of the cancers are in people over the age of 65+. The geriatric population in the USA is supposed to surpass the young population by 2037, and by 2034, children and adults above 65+ will break even. Moreover, as per scientists, there is a high correlation between rising age and cancer development. It is owing to the cell damage which happens over time, and one become aged, the cells have higher chances of turning into “melanoma cells.” 

5HT3 Receptor Antagonists Market Challenges

The side effects post-consumption of 5HT3 drugs poses a grave challenge for the market. 

The most common adverse reactions reported by the patient’s post-consumption of 5HT3 receptor antagonists are headache- (9%-27%); fatigue- (9%-13%); malaise (9%- 13%), and lastly constipation. Moreover, various patients have reported drowsiness, dizziness, anxiety, urinary retention, and hypoxia as more common side effects. Moreover, cases related to arrhythmia have been reported when the 5HT3 is used with other interval prolonging agents. Serotonin syndrome is another prominent after-effect noticed post-anesthesia. Furthermore, this condition appears to be from the concomitant use of serotonergic medications, such as SSRIs.

5HT3 Receptor Antagonists Market Competitive Landscape

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the 5HT3 Receptor antagonist receptor Market. The top 10 5HT3 Receptor antagonist receptor companies are-

  2. MedKoo Biosciences Inc.
  3. Cipla Inc.
  4. Helsinn Healthcare SA
  5. Sanofi
  6. F. Hoffmann-La Roche Ltd
  7. MEDNAX Services
  8. Kyowa Kirin Inc.
  9. Heron Therapeutics Inc.
  10. GlaxoSmithKline plc.
  11. Fortovia Therapeutics Inc.

Recent Developments

  • In August 2020, Helsinn announced a new IV injection to treat nausea and vomiting. It is to be used in applications treating CINV, RINV, and even in post-operative care. The product requires no refrigeration during delivery. Moreover, it is compatible with dexamethasone sodium phosphate.
  • In October 2020, Cipla launched Ondansetron. An oral drug to treat the causes of nausea and vomiting from surgery, cancer chemotherapy, and radiation treatment.

Relevant Titles

Cancer Testing and Screening Market- Forecast (2021-2026)

Report Code- HCR 0078

Cancer Immunotherapy Market- Forecast (2021-2026)

Report Code- HCR 0197

For more Lifesciences and Healthcare Market reports, please click here

1. 5HT3 Receptor Antagonists Market- Overview
    1.1 Definitions and Scope
2. 5HT3 Receptor Antagonists Market- Executive Summary
    2.1 Market Revenue, Market Size, and Key Trends
    2.2 Key trends by Product Type
    2.3 Key trends by Application
    2.4 Key trends by Route of Administration
    2.5 Key trends by Distribution Channel 
    2.6 Key trends by Geography
3. 5HT3 Receptor Antagonists Market- Comparative Analysis
    3.1 Company Benchmarking – Key Companies
    3.2 Financial Analysis– Key Companies
    3.3 Market Share Analysis– Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis- Average Selling Price
4. 5HT3 Receptor Antagonists Market- Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
    4.1.1 Investment
    4.1.2 Revenue
    4.1.3 Venture Capital and Funding Scenario
5. 5HT3 Receptor Antagonists Market– Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. 5HT3 Receptor Antagonists Market- Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. 5HT3 Receptor Antagonists Market– Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. 5HT3 Receptor Antagonists Market– By Product Type (Market Size –$Million/$Billion)
    8.1 First Generation Serotonin Blockers
    8.2 Second Generation Serotonin Blockers
9. 5HT3 Receptor Antagonists Market– By Application (Market Size –$Million/$Billion)
    9.1 Chemotherapy-Induced Nausea and Vomiting (CINV)
    9.2 Radiation-Induced Nausea and Vomiting (RINV)
    9.3 Post- Operative Nausea and Vomiting (PONV) 
10. 5HT3 Receptor Antagonists Market– By Route of Administration (Market Size –$Million/$Billion)
    10.2 Topical Patches
    10.3 Oral
11. 5HT3 Receptor Antagonists Market– By Distribution Channel (Market Size –$Million/$Billion)
    11.1 Hospital Pharmacy
    11.2 Drugstore
    11.3 Online Pharmacy
    11.4 Others
12. 5HT3 Receptor Antagonists Market- By Geography (Market Size –$Million/$Billion)
    12.1North America
        12.1.1 U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 U.K.
        12.2.2 Germany
        12.2.3 France
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 India
        12.3.3 Japan
        12.3.4 South Korea
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Rest of South America
    12.5 Rest of the World
        12.5.1 Middle East
        12.5.2 Africa
13. 5HT3 Receptor Antagonists Market- Entropy
14. 5HT3 Receptor Antagonists Market– Industry/Segment Competition Landscape Premium 
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key companies
        14.1.3 Market Share by Countries – Key Companies
        14.1.4 Competition Matrix
        14.1.5 Best Practices for Companies
15. 5HT3 Receptor Antagonists Market– Key Company List by Country Premium Premium
16. 5HT3 Receptor Antagonists Market Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.